Advertisement
Document › Details
MYR GmbH. (6/10/20). "Press Release: MYR Pharmaceuticals Has Incorporated Its First European Subsidiary in France". Bad Homburg.
Region | Paris | |
Country | France | |
Organisation | MYR GmbH (MYR Pharmaceuticals) | |
Group | Gilead Sciences (Group) | |
Organisation 2 | MYR Pharmaceuticals France SAS | |
Group | Gilead Sciences (Group) | |
Product | Hepcludex® (formerly Myrcludex B) | |
Product 2 | virostatic agent | |
Person | Vogel, Florian (MYR Pharmaceuticals 202006 CCO) | |
Person 2 | Christély, Thomas (MetrioPharm 202108– CEO before MYR GmbH + Atugen AG) | |
MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to announce the establishment of its wholly owned subsidiary MYR Pharmaceuticals France SAS, located in Paris (France).
Today, around 15-20 million people worldwide are chronically infected with the hepatitis D virus for whom no approved therapies are available. The company's lead compound Hepcludex® (international nonproprietary name/INN = bulevirtide, formally known as Myrcludex B) is a first-in-class entry inhibitor for the treatment of chronic HBV and HDV infection. The technology was originally developed at the University of Heidelberg (Germany) and INSERM (France). For MYR Pharmaceuticals, the creation of its first European subsidiary represents its commitment to help the French patients suffering from HBV/HDV coinfection.
"We are very pleased to announce the foundation of our French subsidiary. The subsidiary builds the backbone for providing the innovative therapy to patients in need. We are thankful for the support from authorities, regulatory bodies, physicians, patient organizations and all members of the professional medical community in France and look forward to continuing our collaboration," commented Florian Vogel, Chief Commercial Officer at MYR Pharmaceuticals.
About Hepcludex® (INN = bulevirtide)
Hepcludex® represents the most clinically advanced novel approach for the treatment of hepatitis B and D, and is currently in a Phase 3 study in the indication of chronic HDV. The drug inhibits the NTCP receptor on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Hepcludex® has received Orphan Drug Designation for treatment of HDV infection from the European Medicines Agency (EMA) and from the U.S. Food & Drug Administration (FDA). In addition, the EMA has granted PRIority MEdicines (PRIME) scheme eligibility.
The positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of EMA regarding the Conditional Marketing Authorization (CMA) was published May 29th 2020.
About MYR Pharmaceuticals
MYR Pharmaceuticals is headquartered in Bad Homburg (Germany). The company started operations in 2011 and is supported by venture capital investors such as the High-Tech-Gründerfonds and Maxwell Biotech Venture Fund. More information available at http://myr-pharma.com/.
Contact Details
Thomas Christély, CFO
Phone: +49 (0)6172-4959811
Email: info@myr-pharma.com
Record changed: 2023-06-05 |
Advertisement
More documents for Gilead Sciences (Group)
- [1] Hookipa Pharma Inc.. (12/21/23). "Press Release: Hookipa Pharma Announces $21.25 Million Equity Investment from Gilead Sciences". New York, NY & Vienna....
- [2] Hookipa Pharma Inc.. (1/4/23). "Press Release: Hookipa Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine". New York, NY & Vienna....
- [3] BioNTech SE. (7/19/21). "Press Release: BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD". Mainz & Santo Monica, CA....
- [4] Gilead Sciences, Inc.. (12/10/20). "Press Release: Gilead Sciences to Acquire MYR GmbH". Foster City, CA & Bad Homburg....
- [5] MYR GmbH. (8/4/20). "Press Release: MYR Pharmaceuticals Receives Conditional Marketing Authorization by the European Commission for Hepcludex". Bad Homburg....
- [6] Gilead Sciences, Inc.. (1/30/20). "Press Release: Sandra Horning, MD, Joins Gilead Sciences’ Board of Directors". Foster City, CA....
- [7] Gilead Sciences, Inc.. (7/19/19). "Press Release: Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis". Foster City, CA....
- [8] Gemoab GmbH. (7/16/19). "Press Release: Gemoab Announces the Appointment of Oncology Expert Michael Pehl as Chief Executive Officer". Dresden....
- [9] Hookipa Pharma Inc.. (5/8/19). "Press Release: Hookipa Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead". New York, NY & Vienna....
- [10] Gilead Sciences, Inc.. (4/12/19). "Press Release: Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH". Foster City & Bagsværd....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top